Literature DB >> 28844339

Advances in Merkel cell carcinoma from a pathologist's perspective.

Sarah Kay Barksdale1.   

Abstract

Merkel cell carcinoma (MCC) is a rarely made but potentially devastating diagnosis. While local disease might be cured by surgery and radiotherapy, advanced disease is usually rapidly progressive and fatal. Until very recently, the only approach to metastatic MCC was cytotoxic chemotherapy with results so disappointing that current treatment guidelines discourage its use and recommend clinical trial as a more viable treatment option. Fortunately, recent advances in the understanding of the molecular pathogenesis of this tumour have produced a wide variety of experimental treatments for MCC, some of which are quite promising. The most current information regarding the diagnosis, staging, management of this tumour is briefly presented as well as new insights into the molecular basis of MCC and therapeutic approaches to MCC.
Copyright © 2017 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Merkel cell carcinoma; check point inhibitors; personalised therapy

Mesh:

Year:  2017        PMID: 28844339     DOI: 10.1016/j.pathol.2017.07.003

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

Review 1.  [Merkel-cell carcinoma].

Authors:  I Moll
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

2.  Merkel Cell Carcinoma Metastatic to Pleural Fluid: A Case Report.

Authors:  Ye-Young Rhee; Soo Hee Kim; Eun Kyung Kim; Se Hoon Kim
Journal:  J Pathol Transl Med       Date:  2017-11-23

Review 3.  Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America.

Authors:  Rafael A Schmerling; Jose G Casas; Gabriela Cinat; Fabio Ernesto Grosso Ospina; Luiza E B P Kassuga; Jorge Luis Martinez Tlahuel; Luis Daniel Mazzuoccolo
Journal:  J Glob Oncol       Date:  2018-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.